Cuban anti-pneumococcal vaccine to apply for sanitary registration

Havana, Jan 28 (RHC) the Cuban anti-pneumococcal vaccine, Quimi-Vio, is close to requesting sanitary registration with the National Regulatory Authority, the Finlay Vaccine Institute (IFV) reported.

According to what was expressed by Yuri Valdés Balbín, deputy director of the institution during the trials the injectable demonstrated safety, generating expected mild adverse effects at the local level, the IFV explained on Twitter.

It protects against seven of the most infectious and highly prevalent serotypes of the pneumococcal bacterium (it is as if seven vaccines were developed in one), the pathogen that causes most pneumonia and bacterial meningitis in children, as well as bloodstream infections, otitis media, sinusitis, and bronchitis, he noted.

He said that in terms of adverse events, it only caused the same reactions as any other vaccine, particularly pain in the area where it was applied and redness, while, from a systemic point of view, the most common in some cases was fever.

Regarding efficacy, notorious evidence of immunogenicity with an impact on the disease was observed, confirming the protection of the vaccine candidate against pneumococcus.

Once the vaccine obtains its sanitary registration, it will be applied first in the age group of one to five years and, later, in infants in the first semester of life.

Quimi-Vio grants the country technological sovereignty to combat diseases caused by this bacterium which, according to the World Health Organization (WHO), causes around 1.6 million deaths worldwide every year, a good part of them from children under five years of age. (Text: ACN)